Blood-based tests show strong promise for dementia diagnosis—but population diversity matters

In a study published today, Friday, February 13, 2026, in the journal Nature Aging, researchers show that blood-based biomarkers can support accurate dementia diagnosis across diverse populations when integrated with cognitive and neuroimaging measures. Blood-based biomarkers are emerging as one of the most promising advances for the global diagnosis of dementia, including Alzheimer's disease and frontotemporal lobar degeneration. These tests offer a more accessible, scalable, and cost-effective alternative to traditional diagnostic tools such as brain imaging or cerebrospinal fluid analysis.